The negative syndrome as a dimension: Factor analyses of PANSS in major depressive disorder and organic brain disease compared with negative syndrome structures found in the schizophrenia literature

Cognitive and Behavioral Neurology

Volumn 20, Issue 2, 2007, Pages 113-120

  Milak, Matthew S ^a   Aniskin, Dmitry B ^a   Eisenberg, Daniel P ^a   Prikhojan, Alexander ^a   Cohen, Lisa J ^a   Yard, Samantha S ^a   Galynker, Igor I ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Dementia; Depression; Negative syndrome; Schizophrenia; Stroke

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXPLORATORY RESEARCH; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NEGATIVE SYNDROME; NEUROLOGIC EXAMINATION; ORGANIC BRAIN SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCORING SYSTEM;

ADULT; AFFECTIVE SYMPTOMS; AGED; AGED, 80 AND OVER; CEREBROVASCULAR ACCIDENT; DEMENTIA; DEPRESSIVE DISORDER, MAJOR; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SYNDROME;

EID: 34250165763     PISSN: 15433633     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNN.0b013e3180653c35     Document Type: Article

References (54)

1. Galynker II, Cohen LJ, Cai J. Negative symptoms in patients with major depressive disorder: a preliminary report. Neuropsychiatry Neuropsychol Behav Neurol. 2000;13:171-176.
2. Galynker II, Dutta E, Vilkas N, et al. Hypofrontality and negative symptoms in patients with dementia of Alzheimer type. Neuropsychiatry Neuropsychol Behav Neurol. 2000;13:53-59.
3. Kitamura T, Suga R. Depressive and negative symptoms in major psychiatric disorders. Comprehens Psychiatry. 1991;32:88-94.
4. Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci. 1997;9:231-239.
5. Galynker I, Levinson I, Miner C, et al. Negative symptoms in patients with basal ganglia strokes. Neuropsychiatry Neuropsychol Behav Neurol. 1995a;8:113-117.
6. Galynker I, Prikhojan A, Phillips E, et al. Negative symptoms in stroke patients and length of hospital stay. J Nerv Ment Dis. 1997;185:616-621.
7. Ellason J, Ross C. Positive and negative symptoms in dissociative identity disorder and schizophrenia: a comparative analysis. J Nerv Ment Dis. 1995;183:236-241.
8. Doody RS, Massman P, Mahurin R, et al. Positive and negative neuropsychiatric features in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995;7:54-60.
9. Hasui C, Sakamoto S, Sugiura T, et al. Burden on family members of the mentally ill: a naturalistic study in Japan. Compr Psychiatry. 2002;43:219-222.
10. Greene JG, Smith S, Gardiner M, et al. Measuring behavioral disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing. 1982;11:121-126.
11. Jackson H. Remarks on evolution and dissolution of the nervous system. J Mental Sci. 1894;33:25-48.
12. Kuperberg GR, Murray R. Advances in the treatment of schizophrenia. Br J Clin Pract. 1996;50:315-323.
13. Rankin ED, Layne RD. The use of olanzapine in the treatment of negative symptoms in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2005;17:423-424.
14. Nelson HE, Pantelis C, Carruthers K, et al. Cognitive functioning and symptomatology in chronic schizophrenia. Psychol Med. 1990;20:357-365.
15. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3:243-254.
16. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38:143-162.
17. Roth RM, Flashman LA, Saykin AJ, et al. Apathy in schizophrenia: reduced frontal lobe volume and neuropsychological deficits. Am J Psychiatry. 2004;161:157-159.
18. Benoit M, Clairet S, Koulibaly PM, et al. Brain perfusion correlates of the Apathy Inventory dimensions of Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:864-869.
19. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Pakinson's disease. J Neuropsychiatry Clin Neurosci. 2001;13:42-49.
20. Kay SR, Sevy S. Pyramidal model of schizophrenia. Schizophr Bull. 1990;16:537-545.
21. Bell MD, Lysaker PH, Beam-Goulet JL, et al. Five-component model of schizophrenia: assessing the factorial invariance of the Positive and Negative Syndrome Scale. Psychiatry Res. 1994;52:295-303.
22. Lindenmayer J-P, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14:229-234.
23. White L, Harvey PD, Opler L, et al. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. Psychopathology. 1997;30:263-274.
24. Lancon C, Aghababian V, Llorca PM, et al. Factorial structure of the Positive and Negative Syndrome Scale (PANSS): a forced five-dimensional factor analysis. Acta Psychiatr Scand. 1998;97:369-376.
25. Dollfus S, Petit M, Lesieur P, et al. Principal-component analysis of PANSS and SANS-SAPS global ratings in schizophrenic patients. Eur Psychiatry. 1991;6:251-259.
26. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallelgroup study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166:712-726.
27. Lindstrom E, von Knorring L. Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia. Nord J Psychiatry. 1993;47:257-263.
28. Peralta V, Cuesta MJ. Psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in schizophrenia. Psychiatry Res. 1994;53:31-40.
29. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538.
30. Klapal M, Eggers C, Bunk D, et al. Funf-Faktoren-Modell kindlicher Schizophrenien. Nervenarzt. 1998;69:238-242.
31. Higashima M, Urata K, Kawasaki Y, et al. P300 and the thought disorder factor extracted by factor-analytic procedures in schizophrenia. Biol Psychiatry. 1998;44:115-120.
32. Lindenmayer JP, Bernstein-Hyman R, Grochowski S. A new five factor model of schizophrenia. Psychiatr Q. 1994;65:299-322.
33. Dollfus S, Petit M. Principal-component analyses of PANSS and SANS-SAPS in schizophrenia: their stability in an acute phase. Eur Psychiatr. 1995;10:97-106.
34. Fredrikson D, Steiger J, MacEwan G, et al. PANSS symptom factors in schizophrenia. Schizophr Res. 1997;24:15-16.
35. Lancon C, Auquier P, Nayt G, et al. Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res. 2000;42:231-239.
36. Mass R, Schoemig T, Hitschfeld K, et al. Psychopathological syndromes of schizophrenia: evaluation of the dimensional structure of the Positive and Negative Syndrome Scale. Schizophr Bull. 2000;26:167-177.
37. Lykouras L, Oulis P, Psarros K, et al. Five-factor model of schizophrenic pathology: how valid is it? Eur Arch Psychiatry Clin Neurosci. 2000;250:93-100.
38. Wolthaus JE, Dingemans PM, Schene AH, et al. Component structure of the Positive and Negative Syndrome Scale (PANSS) in patients with recent onset schizophrenia and spectrum disorders. Psychopharmacology. 2000;150:399-403.
39. Emsley R, Rabinowitz J, Torreman M. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr Res. 2003;61:47-57.
40. Lee KH, Harris AW, Loughland CM, et al. The five symptom dimensions and depression in schizophrenia. Psychopathology. 2003;36:226-233.
41. van der Gaag M, Cuijpers A, Hoffman T, et al. The five-factor model of the Positive and Negative Syndrome Scale I. Schizophr Res. 2006;85:273-279.
42. van der Gaag M, Hoffman T, Remijsen M, et al. The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross validation of a revised model. Schizophr Res. 2006;85:280-287.
43. Tabachnik BG, Fidell LS, eds. Using Multivariate Statistics. 4th ed. Needham Heights, MA: Allyn & Bacon; 2001.
44. Brodaty H, Sachdev PS, Withall A, et al. Frequency and clinical, neuropsychological and neuroimaging correlates of apathy following stroke - the Sydney Stroke Study. Psychol Med. 2005;35:1707-1716.
45. Reichman WE, Coyne AC, Amirneni S, et al. Negative symptoms in Alzheimer's disease. Am J Psychiatry. 1996;153:424-426.
46. Sultzer DL, Levin HS, Mahler ME, et al. A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. Am J Psychiatry. 1993;150:1806-1812.
47. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
48. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (Revised). 3rd ed. Washington, DC: American Psychiatric Association; 1987.
49. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987;13:261-275.
50. Crook TH III, Feher EP, Larrabee GJ. Initial validation of the MAC-P: a new clinician-rated scale for cognitive and affective changes in dementia. Clin Neuropsychol. 1993;7:420-429.
51. Gerbaldo H, Helisch A, Schneider B, et al. Subtypes of negative symptoms: the primary subtype in schizophrenic and non-schizophrenic patients. Prog NeuroPsychopharmacol Biol Psychiatry. 1994;18:311-320.
52. Galynker I, Prikhojan A. Overlap of negative and depressive symptoms in non-schizophrenic patients. Dir Psychiatry. 1999;18:337-349.
53. van Praag HM, Flentge F, Korf J, et al. The influence of probenecid on the metabolism of serotonin, dopamine and their precursors in man. Psychopharmacologia. 1973;33:141-151.
54. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophrenia Bull. 2006;32:238-245.